Literature DB >> 35481752

Anti-Mycobacterium abscessus Activity of Tuberculosis F-ATP Synthase Inhibitor GaMF1.

Priya Ragunathan1, Thomas Dick2,3,4, Gerhard Grüber1.   

Abstract

New drug targets and molecules with bactericidal activity are needed against the respiratory mycobacterial pathogen Mycobacterium abscessus. Employing a lead repurposing strategy, the antituberculosis compound GaMF1 was tested against M. abscessus. Whole-cell and ATP synthesis assays demonstrated that GaMF1 inhibits growth and kills M. abscessus by targeting the F-ATP synthase. GaMF1's anti-M. abscessus activity increased in combination with clofazimine, rifabutin, or amikacin. The study expands the repertoire of anti-M. abscessus compounds targeting oxidative phosphorylation.

Entities:  

Keywords:  F-ATP synthase; Mycobacterium abscessus; bioenergetics; multidrug resistance; nontuberculous mycobacteria; γ subunit inhibitor

Mesh：

Substances：

Year:  2022        PMID： 35481752      PMCID： PMC9112937          DOI： 10.1128/aac.00018-22

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  28 in total

1.  In Vitro Comparison of Ertapenem, Meropenem, and Imipenem against Isolates of Rapidly Growing Mycobacteria and Nocardia by Use of Broth Microdilution and Etest.

Authors:  Barbara A Brown-Elliott; Jessica Killingley; Sruthi Vasireddy; Linda Bridge; Richard J Wallace
Journal:  J Clin Microbiol       Date:  2016-04-06       Impact factor: 5.948

2.  The Unique C-Terminal Extension of Mycobacterial F-ATP Synthase Subunit α Is the Major Contributor to Its Latent ATP Hydrolysis Activity.

Authors:  Chui-Fann Wong; Gerhard Grüber
Journal:  Antimicrob Agents Chemother       Date:  2020-11-17       Impact factor: 5.191

3.  In vitro drug susceptibility of 40 international reference rapidly growing mycobacteria to 20 antimicrobial agents.

Authors:  Hui Pang; Guilian Li; Li Wan; Yi Jiang; Haican Liu; Xiuqin Zhao; Zhongfu Zhao; Kanglin Wan
Journal:  Int J Clin Exp Med       Date:  2015-09-15

4.  Reduction of clofazimine by mycobacterial type 2 NADH:quinone oxidoreductase: a pathway for the generation of bactericidal levels of reactive oxygen species.

Authors:  Takahiro Yano; Sacha Kassovska-Bratinova; J Shin Teh; Jeffrey Winkler; Kevin Sullivan; Andre Isaacs; Norman M Schechter; Harvey Rubin
Journal:  J Biol Chem       Date:  2010-12-30       Impact factor: 5.157

5.  Structure of mycobacterial ATP synthase bound to the tuberculosis drug bedaquiline.

Authors:  Hui Guo; Gautier M Courbon; Stephanie A Bueler; Juntao Mai; Jun Liu; John L Rubinstein
Journal:  Nature       Date:  2020-12-09       Impact factor: 49.962

6.  Preliminary Results of Bedaquiline as Salvage Therapy for Patients With Nontuberculous Mycobacterial Lung Disease.

Authors:  Julie V Philley; Richard J Wallace; Jeana L Benwill; Varsha Taskar; Barbara A Brown-Elliott; Foram Thakkar; Timothy R Aksamit; David E Griffith
Journal:  Chest       Date:  2015-08       Impact factor: 9.410

7.  Clofazimine Prevents the Regrowth of Mycobacterium abscessus and Mycobacterium avium Type Strains Exposed to Amikacin and Clarithromycin.

Authors:  Beatriz E Ferro; Joseph Meletiadis; Melanie Wattenberg; Arjan de Jong; Dick van Soolingen; Johan W Mouton; Jakko van Ingen
Journal:  Antimicrob Agents Chemother       Date:  2015-12-07       Impact factor: 5.191

8.  Draft Genome Sequence of Mycobacterium abscessus Bamboo.

Authors:  Michelle Yee; David Klinzing; Jun-Rong Wei; Martin Gengenbacher; Eric J Rubin; Thomas Dick
Journal:  Genome Announc       Date:  2017-05-18

9.  Rifabutin Is Active against Mycobacterium abscessus Complex.

Authors:  Dinah Binte Aziz; Jian Liang Low; Mu-Lu Wu; Martin Gengenbacher; Jeanette W P Teo; Véronique Dartois; Thomas Dick
Journal:  Antimicrob Agents Chemother       Date:  2017-05-24       Impact factor: 5.191

10.  Structure of the ATP synthase from Mycobacterium smegmatis provides targets for treating tuberculosis.

Authors:  Martin G Montgomery; Jessica Petri; Tobias E Spikes; John E Walker
Journal:  Proc Natl Acad Sci U S A       Date:  2021-11-23       Impact factor: 11.205
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.